Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jan 1;11(1):229-240.
doi: 10.7150/jca.35537. eCollection 2020.

HIF-1α Promotes the Metastasis of Esophageal Squamous Cell Carcinoma by Targeting SP1

Affiliations

HIF-1α Promotes the Metastasis of Esophageal Squamous Cell Carcinoma by Targeting SP1

Xueting Hu et al. J Cancer. .

Abstract

Background: In microenvironment of malignant tumors, Hypoxia-Inducible Factors (HIF), most importantly HIF-1α, play an important role in regulation of adaptive biological response to hypoxia, promoting angiogenesis and metastasis. However, the underlying mechanism that HIF-1α regulates metastasis needs to be further clarified. Methods: The expressions of HIF-1α and SP1 were detected in 182 samples of esophageal squamous cell carcinoma (ESCC) and adjacent normal tissues by immunohistochemistry (IHC), and the correlation between the expression levels of HIF-1α and SP1 was analyzed. The expression of HIF-1α in ESCC cell lines TE1 and KYSE30 was then detected using qRT-PCR and western blot. The potential binding sites of HIF-1α on the SP1 promoter were analyzed using UCSC and JASPAR databases, verified by chromosomal immunoprecipitation (ChIP) assay and qRT-PCR. The effects of HIF-1α and SP1 on ESCC cell migration and invasion were then tested with Transwell and Matrigel experiments. Results: The expression of HIF-1α in cancer tissues is higher than adjacent normal tissues, and is correlated with metastasis, recurrence and poor prognosis. Upon silencing HIF-1α by siRNA, the invasion and migration ability of ESCC cells were significantly inhibited, which could be restored by the overexpression of SP1. Hypoxic conditions significantly increased the expression of HIF-1α and SP1 at both protein and mRNA levels in ESCC cells. HIF-1α enhanced SP1 transcription through binding to the promoter region. The expression of protein and mRNA levels of SP1 was decreased by silencing HIF-1α in cells. In contrast, overexpression of HIF-1α significantly increased the mRNA and protein levels of SP1. The expression of SP1 in ESCC was positively correlated with the protein expression of HIF-1α and poor prognosis. Conclusion: The results of our study indicate that HIF-1α promotes metastasis of ESCC by targeting SP1 in a hypoxic microenvironment. Further study on this mechanism may elucidate the possibility of HIF-1α and SP1 as new targets for the treatment of ESCC.

Keywords: ESCC; HIF-1α; SP1; tumor metastasis.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interest exists.

Figures

Figure 1
Figure 1
The expression of HIF-1α in ESCC tissues and the functions of HIF-1α in ESCC cells. a The expression of HIF-1α in ESCC detected by IHC, and the immunoreactivity score of HIF-1α in ESCC tumor tissues and adjacent normal tissues(n=182); b the 3-year regional recurrence curve of patients with HIF-1α high/low expression; c the 5-year survival curve of patients with HIF-1α high/low expression; d silencing HIF-1α by siRNA significantly suppressed the migration and invasion of TE1 and KYSE30, (n=3). Data represent the mean ± S.D; e overexpression of HIF-1α promoted migration and invasion of TE1 and KYSE30, (n=3). Data represent the mean ± S.D. (** P<0.01, *** P<0.001).
Figure 2
Figure 2
Effects of SP1 overexpression on the migration and invasion of hypoxic ESCC cells. a, b migration and invasion of TE1 and KYSE30 cells can be blocked by HIF-1α silencing, and can be rescued by SP1 overexpression (n=3). Data represent the mean ± S.D. (*** P<0.001).
Figure 3
Figure 3
HIF-1α up-regulates the protein expression of SP1 and its transcriptional activity by directly binding to the SP1 promoter. a Schematic diagram depicting the positions of the primers used for the ChIP assay; b, c ChIP analysis was performed using a negative control immunoglobulin G (IgG) or anti- HIF-1α antibody in TE1 cells. Input positive control (anti- ARRDC3 antibodies); d HIF-1α and SP1 mRNA levels under both normoxic and hypoxic conditions were analyzed by real-time PCR. β-Actin was used as the internal control; e HIF-1α and SP1 protein levels under both normoxic and hypoxic conditions(48h) were analyzed by Western blotting. β-Actin was used as the internal control; f a knockdown efficiency of HIF-1α siRNA, and the mRNA levels of SP1 were detected by real-time PCR. β-Actin was used as the internal control (n=3); g a knockdown efficiency of HIF-1α siRNA, and the protein levels of SP1 were analyzed by Western blotting. β-Actin was used as the internal control (n=3); h the efficiency of over expression of HIF-1α, and the protein levels of SP1 were analyzed by Western blotting, the mRNA levels of SP1 were detected by real-time PCR. β-Actin was used as the internal control (n=3). (** P<0.01, *** P<0.001).
Figure 4
Figure 4
Co-expression of HIF-1α and SP1 in ESCC tissues. a The expression of SP1 in ESCC tissues detected by IHC, the immunoreactivity score of SP1 in ESCC tumor tissue and adjacent normal tissue (n=182); b the 3-year regional recurrence curve of patients with SP1 high/low expression; c the 5-year survival curve of patients with SP1 high/low expression; d the expression of HIF-1α and SP1 in ESCC detected by IHC, the immunoreactivity score of SP1 in HIF-1α high expression(n=102) and HIF-1α low expression(n=80) groups; e the correlation between the expression of HIF-1α and SP1 in esophageal cancer tissues; f, g the percent number of high/low expression of HIF-1α and SP1 in metastatic and non-metastatic groups; h the 5-year survival curve of patients with HIF-1α and SP1 positive/negative expression; i the 3-year regional recurrence curve of patients with HIF-1α and SP1 positive/negative expression. (** P<0.01, *** P<0.001).

Similar articles

Cited by

References

    1. Fitzmaurice C, Allen C, Barber RM. et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol. 2017;3:524–8. - PMC - PubMed
    1. Torre LA, Bray F, Siegel RL. et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108. - PubMed
    1. Sjoquist KM, Burmeister BH, Smithers BM. et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2011;12:681–92. - PubMed
    1. Fakhrian K, Ordu AD, Lordick F. et al. Long-term outcomes of trimodality treatment for squamous cell carcinoma of the esophagus with cisplatin and/or 5-FU. StrahlentherOnkol. 2014;190:1133–40. - PubMed
    1. Mariette C, Piessen G, Triboulet JP. Therapeutic strategies in oesophageal carcinoma: Role of surgery and other modalities. The Lancet Oncology. 2007;8:545–53. - PubMed